Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018
May 08, 2018 02:00 ET
|
Verona Pharma plc
Announced positive top-line data from two Phase 2 clinical trials ahead of schedule Met primary and key secondary endpoints in 403 patient Phase 2b clinical trial for maintenance treatment of COPD ...
Verona Pharma to Present at Bio€quity Europe 2018
May 04, 2018 08:30 ET
|
Verona Pharma plc
LONDON, May 04, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona Pharma to Announce Operational Update and Financial Results for First Quarter Ended March 31, 2018
May 02, 2018 08:30 ET
|
Verona Pharma plc
LONDON, May 02, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
Verona Pharma Announces Departure of Chief Medical Officer
April 11, 2018 02:00 ET
|
Verona Pharma plc
LONDON, April 11, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or “the Company”), a clinical-stage biopharmaceutical company focused on developing and...
Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPD
March 26, 2018 02:00 ET
|
Verona Pharma plc
Primary endpoint met; RPL554 produced clinically and statistically significant improvements in lung function at all dose levels Clinically relevant secondary endpoints were also met, including...
Verona Pharma to Present at Upcoming Healthcare Investor Conferences
March 15, 2018 08:00 ET
|
Verona Pharma plc
LONDON, March 15, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
Verona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis Patients
March 02, 2018 02:00 ET
|
Verona Pharma plc
LONDON, March 02, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
Verona Pharma plc ("Verona Pharma" or the "Company") Reports Operational Update and Financial Results for Full Year Ended December 31, 2017
February 27, 2018 02:00 ET
|
Verona Pharma plc
LONDON, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona Pharma to Announce Operational Update and Financial Results for Full Year ended December 31, 2017
February 22, 2018 08:45 ET
|
Verona Pharma plc
LONDON, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona Pharma Provides Clinical Development Update
February 13, 2018 02:00 ET
|
Verona Pharma plc
LONDON, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...